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Received January 30, 2015; accepted April 30, 2015AbstractNanoparticles combined with cells, drugs, and specially designed genes provide improved therapeutic efficacy in studies and clinical setting,
demonstrating a new era of treatment strategy, especially in retinal diseases. Nanotechnology-based drugs can provide an essential platform for
sustaining, releasing and a specific targeting design to treat retinal diseases. Poly-lactic-co-glycolic acid is the most widely used biocompatible
and biodegradable polymer approved by the Food and Drug Administration. Many studies have attempted to develop special devices for
delivering small-molecule drugs, proteins, and other macromolecules consistently and slowly. In this article, we first review current progress in
the treatment of age-related macular degeneration. Then, we discuss the function of vascular endothelial growth factor (VEGF) and the
pharmacological effects of anti-VEGF-A antibodies and soluble or modified VEGF receptors. Lastly, we summarize the combination of anti-
angiogenic therapy and nanomedicines, and review current potential targeting therapy in age-related macular degeneration.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Age-related macular degeneration (AMD) is a common
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assyellowish deposit in the macula in dry type and choroidal
neovascularization (CNV) in wet type. Wet AMD, also named
neovascular AMD, is the leading cause of visual impairment
in the elderly in industrialized countries, and results in blurred
central vision due to macular edema from vascular hyper-
permeability and abnormal blood vessel growth behind the
macula.1 Vascular endothelial growth factor (VEGF), a protein
essential in angiogenesis and vascular hyperpermeability, is
highly associated with wet AMD. According to the severity of
wet AMD, several treatment choices are available nowadays,
including intravitreal injection of therapeutic agents, argonociation. All rights reserved.
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therapy with verteporfin, and vitreoretinal surgery as a final
resolution. Argon laser photocoagulation has been used to
directly destroy the abnormal CNV membrane since the
1970s,2 playing an important role in the treatment of wet
AMD before we knew the importance of VEGF. Photocoag-
ulation is now used as a supplement to treat extrafoveal neo-
vascularization and polypoidal choroidal vasculopathy, a
variant of AMD, due to its tissue-destroying effect. Photody-
namic therapy is targeted at the subfoveal CNV to prevent
traditional laser burn in the macula.3 It is performed with the
assistance of an intravenously injected photosensitive agent,
followed by exposure to light of a specific wavelength
(689 nm). However, its clinical application is limited due to its
high cost and possible choroidal ischemia after treatment.4
Considering the pathophysiology of wet AMD, it is
believed that the causes of neovascularization are increased
intraocular concentration of VEGF and macrophage-induced
inflammation within retinal tissues. Thus, intravitreal injec-
tion of anti-VEGF agents and/or anti-inflammatory drugs
(mainly steroids) monthly for at least three times has become a
consensus in the treatment of patients with fresh and recurrent
wet AMD.5 Since intraocular delivery of a steroid may lead to
elevated intraocular pressure or cataract formation, this treat-
ment should be used selectively, especially in young patients.6
In patients with refractory wet AMD presenting severe vitre-
ous hemorrhage and epiretinal CNV membrane,7 vitreoretinal
surgery should be considered to remove the blood and restore
the integrity of the retinal structure.
2. VEGF, anti-VEGF-A antibodies, and soluble or
modified VEGF receptors
VEGF belongs to a growth factor family, which includes
VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth
factor.8 VEGF-A induces hemangiogenesis through VEGF
receptor-2 (VEGFR-2), and VEGF-C/VEGF-D stimulates
lymphangiogenesis through VEGFR-2 and VEGFR-3.9e12
Currently, anti-VEGF agents such as bevacizumab (Avastin,
Genentech, CA, USA), ranibizumab (Lucentis, Genentech,
CA, USA), and aflibercept (Eylea, Regeneron Pharmaceuti-
cals, NY, USA) are available in the market. Bevacizumab is a
whole anti-VEGF-A immunoglobulin, while ranibizumab is a
fab fragment of an antibody against VEGF-A. By contrast,
aflibercept is a new recombinant fusion protein that is
composed of two main components, the VEGF binding por-
tions from the extracellular domains of human VEGFR-1 and
VEGFR-2, which is then fused to the Fc portion of human
immunoglobulin G1.13 Aflibercept has the ability to bind
VEGF-A, VEGF-B, or placental growth factor and to inhibit
angiogenesis. Currently, many studies are comparing the ef-
ficacy and safety of these three drugs.
By contrast, studies have found a common expression of
soluble VEGFRs on the corneal surface. These truncated
forms of VEGFR are formed by alternative splicing or pro-
teolytic shedding, and can block the effect of VEGF ligand by
VEGF trapping, further preventing their binding at membrane-bound VEGFRs. This mechanism helps inhibit angiogenesis
and further maintains avascularity of cornea.14e18 The soluble
truncated form of VEGFR-1 (Flt-1), called fms-like tyrosine
kinase (sFlt-1, sVEGFR-1), has high affinity for VEGF-A.14
VEGFR-2 and VEGFR-3 both have their soluble forms,
sVEGFR-2 and sVEGFR-3, respectively, and can block the
function of VEGF-C.16,18
VEGFR intraceptor can also block VEGF. Lys-Asp-Glu-
Leu (KDEL) is a quadripeptide retention signal that binds
endoplasmic reticulum retention receptors. Thus, proteins
coupled with KDEL cannot be secreted from the endoplasmic
reticulum.19 When domains 2 and 3 of VEGFR-1 are coupled
to KDEL, the recombinant construct can bind VEGF intra-
cellularly and block the function of VEGF. Flt23k (coupled
domains 2e3 of Flt-1 with KDEL) was found to be a potential
therapeutic agent for CNV in primate and murine AMD
models.20
3. Nanotechnology-based drug delivery treatment
Most of the developing intraocular therapies are aiming at
the reduction of macular edema or suppression of CNV
resulting from elevated vitreous VEGF under several condi-
tions, including not only AMD, but also diabetic retinopathy
and retinal venous occlusion. Recently, naturally biodegrad-
able or synthetic nanoparticulated drug delivery systems have
been proposed as promising and alternative drug carriers in the
treatment of retinal diseases. Nanotechnology can create and
combine materials or devices with drugs and specially
designed genes at a size of < 100 nm and, with advantages
such as slow release, better tissue penetration, and higher drug
packing, can help monitor, control, and cure diseases.21 Fig. 1
shows the current applications of nanotechnology in ocular
diseases, and the following section presents the details of
current development of intraocular therapy with the use of
nanomedicines.3.1. Intraocular therapy by intravitreal injectionCurrent nanotechnology-based applications in intraocular
therapy are summarized in Table 1 and described as follows.3.2. VEGF-associated productsNowadays, patients with neovascular AMD can reach better
visual outcomes by the administration of different types of
VEGF antagonists.22 However, these treatments require
frequent injections on a long-term basis, which may lead to
patient noncompliance and increased risks of iatrogenic injury,
such as bleeding, retinal detachment, and even endoph-
thalmitis.23 Therefore, a formulation with a stable, efficient,
yet sustained releasing profile is necessary for the develop-
ment of future therapeutics against AMD.
Poly-lactic acid (PLA) and poly-lactic-co-glycolic acid
(PLGA) are biocompatible and biodegradable polymers,
which have been approved by the Food and Drug Adminis-
tration for use in drug products and widely studied for delivery
Fig. 1. Nanoparticles can contain medication agents and plasmid vectors, or have a ligand coating on their surface. Applications of nanotechnology in ocular
diseases are divided into five parts: (1) nanotechnology-based drug delivery systems have better permeation and longer retention; (2) nanotechnology-based
therapies can supply better surface protection and better coverage; (3) nanoparticles can be used in gene therapy; plasmid vectors in nanoparticles were
phagocytosed by cells, and the genes were further released; (4) ligand-coated nanoparticles have a homing effect and can be applied for target therapies; and (5)
nanotechnology-based therapies can prevent drugs from rapid degradation and further reduce drug toxicity.
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PLGA can be hydrolyzed to form natural metabolites (lactic
and glycolic acids) and is eliminated from the body.25 A
number of approaches have been investigated for the prepa-
ration of drug-encapsulated polymers in the form of micro-
particles and nanoparticles.26,27 The supercritical fluid
technology is applicable for pharmaceutical manufacturingTable 1
Current nanotechnology-based applications in ocular therapy
Group APIs Polymers Techni
Yandrapu et al29 Bevacizumab PLGA/PLA Superc
pressu
techno
Shmueli et al36 Serpin-derived peptide Poly (beta-amino ester),
PBAE, & PLGA
Self-as
microe
Luo et al20 Integrin-binding liner
RGD peptide
PLGA Emuls
evapor
Suen and Chau35 TA Folate-functionalized
poly(ethylene
glycol)-b-polycaprolactone
Nanop
APIs ¼ active pharmaceutical ingredients; PBAE ¼ poly (beta-amino ester); PLA
acetonide; VEGF ¼ vascular endothelial growth factor; RGD = Arg-Gly-Asp; N
nanoparticles loaded with anti-angiogenic plasmid Flt23k and conjugated with Niland generation of microparticle-based formulations for both
small and large molecules.28 While being above their critical
point, supercritical fluids have fluid-like densities and gas-like
diffusivity, which allow sufficient mixing under supercritical
conditions. Yandrapu et al29 prepared PLA nanoparticles in
porous PLGA microparticles (NPinPMP) with bevacizumab
using supercritical carbon dioxide. Supercritical carbonques Significant results
ritical infusion and
re quench
logy
4 mo sustained release of bevacizumab (in vitro).2 mo
release of bevacizumab in rat model (intravitreal
administration)
sembling and
ncapsulation
Zero-order in vitro release
Significantly increased suppression of angiogenesis
(>14 wk)
ification solvent
ation
Restored vision function after treatment with
RGD-Flt23k-NR-nanoparticles in primate & murine
macular degeneration models
recipitation Sustained TA release up to 4 wk at pH 5.5 & 8 wk at pH
7.4
Downregulation of VEGF and upregulation of pigment
epithelium-derived factor lasting for at least 3 wk
¼ poly-lactic acid; PLGA ¼ poly-lactic-co-glycolic acid; TA ¼ triamcinolone
R= Nile Red; RGD-Flt23k-NR-nanoparticles = RGD-functionalized PLGA
e Red.
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cles by about sevenfold, but not that of the drug-coated PLA
nanoparticles. The in vitro release of NPinPMP showed a
sustained release of bevacizumab for 4 months. In addition,
after intravitreal administration of NPinPMP in a rat model,
bevacizumab was detectable for a prominently prolonged
period (2 months), compared with the administration of bev-
acizumab solution alone (2 weeks).
Luo and colleagues20 worked on targeted delivery of
integrin-binding linear RGD (Arg-Gly-Asp) peptide against
VEGF using PLGA nanoparticles with the aid of recombinant
Flt23k intraceptor plasmid, which is capable of homing the
delivery system to neovascular lesions in the retina and
regressing CNV in both primate and murine AMD models.
The delivery system showed no ocular and systemic toxicity.
After intravenous injection, RGD-functionalized nanoparticles
were shown to be localized at CNV lesions. More excitingly,
restoration of vision function after treatment with RGD-Flt23k
nanoparticles was validated in both primate and murine AMD
models. Luo et al's20 results are important in that RGD-
targeted nanoparticles delivering Flt23k intraceptor plasmids
provide a different approach for ocular orientation through
systemic administration (intravenous injection). This treat-
ment can abolish neovascularization and fibrosis in animal
AMD models while preventing serious side effects related to
intraocular injection of anti-VEGF agents.3.3. SteroidsTo reduce the side effects of intravitreal injection of ste-
roids, Daull and colleagues30 used a lipophilic prodrug of
dexamethasone (DXM), dexamethasone palmitate (DXP), for
treatment of macular edema in several animal models,
including rats, rabbits, cats, and minipigs. They tried to
characterize the sustained release capacity, efficacy, and safety
of intravitreal injection of DXP emulsions in preclinical situ-
ations. The results showed good efficacy in both rat and rabbit
models. In addition, the pharmacokinetic data of rabbit pre-
sented sustained DXM concentrations in the retina and
choroid. The DXM concentrations were found to be sufficient
to suppress VEGF-induced vascular hyperpermeability up to 9
months. Therefore, intravitreal injection of DXP emulsion was
efficacious for a sustained drug release, and potentiated the
control of vascular leakage for up to 9 months following only a
single dose of intravitreal injection. Daull et al's30 study
demonstrated that intravitreal injection of DXP emulsion
could be a safe and effective alternative drug delivery platform
for corticosteroids against macular edema.
Ozurdex, an intravitreal DXM implant (Allergan Inc., Irvine,
CA, USA), has been approved for the treatment of macular
edema in branch retinal venous occlusion and central retinal
venous occlusion.31,32 However, it is also regarded as an adjunct
therapy for patients with wet AMD refractory to anti-VEGF
agents. Calvo et al33 found Ozurdex to be effective in vision
stabilization, reduction of intra- and subretinal fluids, and
improvement of central retinal thickness in eyes with refractory
wet AMD. It is a slow-releasing DXM implant that is injectedthrough the pars plana. This implant is composed of a biode-
gradable, PLGA-based (NOVADUR solid polymer delivery
system) copolymer matrix, which helps control the release of
DXM, and allows DXM to maintain a high concentration in the
vitreous during the first 2 months after injection and at a lower
concentration later for up to 6 months.32,34
Recently, Suen and Chau35 developed triamcinolone ace-
tonide (TA)-loaded, folate-modified poly (ethylene glycol)-b-
polycaprolactone (folate-PEG-b-PCL) nanoparticles by nano-
precipitation. A sustained release of TA from the nanoparticles
was achieved for up to 4 weeks at pH 5.5 and 8 weeks at pH
7.4. In the cell (ARPE-19 cells) uptake experiment, down-
regulation of VEGF and upregulation of pigment epithelium-
derived factor, lasted for at least 3 weeks. This nanoparticle-
based TA delivery system was highlighted as a possible
replacement for the current intravitreal injection treatment.
Furthermore, folate modification enhances the solubility of
TA, while the encapsulation of TA reduces its possible
cytotoxicity.3.4. Other materials with antiangiogenic agentsShmueli et al36 discovered several classes of peptides with
very strong antiangiogenic properties. In order to prevent
peptide degradation, serpin-derived peptide was first self-
assembled with positively charged poly (beta-amino ester),
to form the nanoparticles. To further prolong the release, the
manufactured polymerepeptide nanoparticles were then
encapsulated into PLGA microparticles. The peptide-carrying
microparticles showed nearly zero-order release of the peptide
for up to 200 days. In addition, long-term in vivo studies in the
laser-induced neovascularization rat model showed that these
peptide-releasing microparticles suppressed angiogenesis for
> 14 weeks in vivo after a single intravitreal injection,
revealing that the combination of serpin-derived peptide and
biodegradable polymer-based particles was likely to be a
suitable tool for future long-term treatment of chronic ocular
diseases, especially AMD.
Celecoxib is a cyclooxygenase-2 inhibitor, characterized by
its anti-inflammatory, antiproliferative, and anti-VEGF effects
on the retina.37 Palamoor and Jablonski38 prepared celecoxib-
loaded poly (ortho ester) nanoparticles for intraocular drug
delivery against AMD and diabetic retinopathy, the two
leading causes of blindness in the elder. Their nanoparticulated
formulation showed a zero-order release due to surface erosion
and no burst release of celecoxib. Moreover, in the cell-uptake
study, the formulated nanoparticles were not internalized by
Mu¨ller and HEK 293 cells, which implied that these nano-
particles could be a suitable platform for drug delivery specific
to the posterior segment of the eyes against AMD.3.5. Intraocular therapies by other routesAlthough intraocular therapy with intravitreal injection
directly delivers drug compounds to the posterior segment of
the eye, potential side effects limit long-term therapy.23
However, achieving therapeutic concentrations of drugs by
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the presence of ocular barriers.39 Drug administration by
subconjunctival route is less invasive and considered as an
alternative to the intravitreal route, but such treatments require
frequent intervention.40 Subconjunctival administration of
drugs with nanoparticles can be further dispersed in
PLGAePEGePLGA thermosensitive gels to sustain the drug
release.39,41 After injection, these thermogelling systems form
a depot above the sclera and slowly release drugs for the
treatment of diseases in the posterior segment. Boddu et al39
prepared nanoparticulated gel formulations of steroids by
oil-in-water emulsion and dialysis methods using PLGA 50:50
and PLGA 65:35. They found that the nanoparticles suspended
in thermosensitive gels released steroids obeying zero-order
kinetics without an apparent burst effect, and concluded that
these novel systems could provide sustained retinal/choroidal
delivery of a steroid following episcleral administration.
Further studies are needed to evaluate the effects of other
medications, such as anti-VEGF agents, in these thermo-
sensitive nanoparticulate gel systems for creating a safer way
to treat CNV in AMD.
4. Specific targeting therapy for AMD4.1. Complement-associated specific targeting therapySince 2005, several studies have found that AMD is asso-
ciated with a variation in the gene that encodes complement
factor H (CFH), and in patients who have one copy of Y402H
polymorphism, there is a nearly fivefold increase in the risk of
having AMD.42e45 It implies that dysregulation of the com-
plement system has a role in the pathogenesis of AMD. The
most well-known CFH genetic variant of AMD is the Y402H
polymorphism (a tyrosine-to-histidine substitution at amino
acid position 402 within the CFH protein). Besides CFH, other
complement pathways encoding genes such as complement
factor B, C2, C3, and I were also reported to be associated
with the risk of AMD.46 Therefore, molecular targeting of the
complement pathways may help in the prevention and treat-
ment of AMD. Currently, clinical trials of Potentia (C3 in-
hibitor), ARC1905 (C5 inhibitor), eculizumab (humanized
monoclonal antibodies binding C5), Tanox (complement fac-
tor D inhibitor), and TA106 (complement factor B inhibitor)
are in process.47 C5a receptor antagonists, JSM-7717 and JPE-
1375, are also currently in preclinical assessment.47
Regarding CFH, Wyatt et al48 used quantitative yeast two-
hybrid and enzyme-linked immunosorbent assays with
different recombinant protein constructs, finding higher af-
finity of Fib3 for the disease-related CFH 402H variant. In
two AMD tissue donors who were homozygous for CFH
402H (H/H), colocalization of CFH and Fib3 in globular
deposits within soft drusen was also observed, which was
distinct from those seen in eyes with Y/Y and H/Y geno-
types. It was concluded that CFH 402H/Fib3 interaction
could aggregate the development of soft drusen and could be
a target for therapeutic intervention.4.2. Interleukin-17AMD is thought to be associated with the inflammatory
response in the macula, where several inflammatory signals
are involved, such as interleukin (IL). The IL-17 cytokine
family contained six members named AeF, among which IL-
17A is the main cytokine. IL-17A and IL-17 receptor (R)-C
increase in AMD eyes and blood, implying IL-17 involvement
in AMD pathogenesis. Targeting IL-17, IL-17R-C, or cells
producing IL-17 may lessen retinal degeneration and could be
considered as a potential therapeutic target for AMD.494.3. Apurinic endonuclease 1/redox factor-1Inhibition of the redox function of apurinic endonuclease 1/
redox factor-1 (APE1/Ref-1) can suppress endothelial angio-
genesis and promote neuronal cell recovery, and is regarded as
a potential treatment for AMD. Li et al50 found that a small-
molecule compound E3330, a specific inhibitor of APE1
redox function, can regulate retinal pigment epithelium (RPE)
cell response to oxidative stress. E3330 can block sublethal
doses of oxidized low-density lipoprotein, decrease the pro-
liferation decline and aging of RPEs, and lessen intracellular
reactive oxygen species, monocyte chemoattractant protein-1,
VEGF, and nuclear factor-kB p65 in RPEs. An animal study
also demonstrated that intravitreal injection of E3330 could
effectively treat laser-induced CNV in mouse eyes.4.4. Rap1 GTPaseDysfunction of barrier of RPE contributes to one of the
mechanisms of development of AMD. Regulation of endo-
thelial and epithelial cell junctions is associated with Rap1
GTPase, which has two isoforms, Rap1A and Rap1B.
Wittchen et al51 used shRNA of Rap1 isoforms in cultured
human RPE cells and knockout mouse models to test the role
of Rap1 in RPE cells. They found that Rap1A and Rap1B are
involved in steady-state barrier integrity and dynamic junc-
tional responses of RPE cells, respectively. In the laser injury
model, Rap1b(/) mice had larger CNV volumes, compared
to wild-type or Rap1a(/) mice. Intravitreal injection of a
Rap1 activator, a cAMP analog (8CPT-20-O-Me-cAMP), could
significantly reduce the CNV volume. They concluded that
8CPT-20-O-Me-cAMP might be a potential treatment option
for AMD.
In conclusion, to date, anti-VEGF drugs are the most
widely used medications for neovascular AMD. However,
there are still limitations in the clinical use of these drugs.
Additionally, there is still no promising treatment for dry
AMD. In recent years, nanotechnology-based drug delivery
treatments for intraocular therapies of AMD have attracted a
great deal of interests. PLA- and PLGA-based drug delivery
systems are under investigation. We have summarized the
recent developments of nanotechnology-based drug delivery
treatments and specific targeting therapy of AMD in this
article. We hope that one day these advancements will have
640 T.-C. Lin et al. / Journal of the Chinese Medical Association 78 (2015) 635e641great outcomes in treating this common and destructive retinal
disorder.
References
1. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS,
et al. Causes and prevalence of visual impairment among adults in the
United States. Arch Ophthalmol 2004;122:477e85.
2. Macular Photocoagulation Study Group. Laser photocoagulation of sub-
foveal recurrent neovascular lesions in age-related macular degeneration.
Results of a randomized clinical trial. Arch Ophthalmol 1991;109:
1232e41.
3. Kaiser PK, Treatment of Age-Related Macular Degeneration with
Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of sub-
foveal choroidal neovascularization in age-related macular degeneration:
5-year results of two randomized clinical trials with an open-label
extensiondTAP report no. 8. Graefes Arch Clin Exp Ophthalmol
2006;244:1132e42.
4. Veritti D, Lanzetta P. Triple therapy for anti-vascular endothelial growth
factor nonresponders in neovascular age-related macular degeneration:
impact of different photodynamic therapy parameters. Ophthalmologica
2013;230:131e7.
5. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic
agents. Retina 2009;29:875e912.
6. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular
oedematous and neovascular diseases. Acta Ophthalmol Scand
2005;83:645e63.
7. Jung JH, Lee JK, Lee JE, Oum BS. Results of vitrectomy for breakthrough
vitreous hemorrhage associated with age-related macular degeneration
and polypoidal choroidal vasculopathy. Retina 2010;30:865e73.
8. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial
growth factor (VEGF) and its receptors. FASEB J 1999;13:9e22.
9. Goldman J, Rutkowski JM, Shields JD, Pasquier MC, Cui Y,
Schmokel HG, et al. Cooperative and redundant roles of VEGFR-2 and
VEGFR-3 signaling in adult lymphangiogenesis. FASEB J 2007;21:
1003e12.
10. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, et al.
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyro-
sine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc
Natl Acad Sci U S A 1998;95:548e53.
11. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, et al. A
novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4
(VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J
1996;15:290e8.
12. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor
(VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-
angiogenic therapies. Genes Cancer 2011;2:1097e105.
13. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al.
Binding and neutralization of vascular endothelial growth factor (VEGF)
and related ligands by VEGF trap, ranibizumab and bevacizumab.
Angiogenesis 2012;15:171e85.
14. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, et al.
Corneal avascularity is due to soluble VEGF receptor-1. Nature
2006;443:993e7.
15. Ambati BK, Patterson E, Jani P, Jenkins C, Higgins E, Singh N, et al.
Soluble vascular endothelial growth factor receptor-1 contributes to the
corneal antiangiogenic barrier. Br J Ophthalmol 2007;91:505e8.
16. Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A,
et al. Alternatively spliced vascular endothelial growth factor receptor-2 is
an essential endogenous inhibitor of lymphatic vessel growth. Nat Med
2009;15:1023e30.
17. Pavlakovic H, Becker J, Albuquerque R, Wilting J, Ambati J. Soluble
VEGFR-2: an antilymphangiogenic variant of VEGF receptors. Ann N Y
Acad Sci 2010;1207(Suppl. 1):E7e15.
18. Singh N, Tiem M, Watkins R, Cho YK, Wang Y, Olsen T, et al. Soluble
vascular endothelial growth factor receptor 3 is essential for corneal
alymphaticity. Blood 2013;121:4242e9.19. Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, Amin S, et al. Nano-
particles sustain expression of Flt intraceptors in the cornea and inhibit
injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci
2007;48:2030e6.
20. Luo L, Zhang X, Hirano Y, Tyagi P, Barabas P, Uehara H, et al. Tar-
geted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis
in primate and murine macular degeneration. ACS Nano
2013;7:3264e75.
21. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanotechnology in
ophthalmology. Can J Ophthalmol 2010;45:457e76.
22. Frampton JE. Ranibizumab: a review of its use in the treatment of
neovascular age-related macular degeneration. Drugs Aging 2013;30:
331e58.
23. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neo-
vascularization: promises and potential problems. JAMA 2005;293:1509e13.
24. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegrad-
able controlled drug delivery carrier. Polymers (Basel) 2011;3:1377e97.
25. Giordano GG, Chevez-Barrios P, Refojo MF, Garcia CA. Biodegradation
and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-
glycolic) acid microspheres. Curr Eye Res 1995;14:761e8.
26. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and
microparticles sustain retinal delivery of budesonide, a corticosteroid
capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci
2003;44:1192e201.
27. Ungaro F, d'Angelo I, Miro A, La Rotonda MI, Quaglia F. Engineered
PLGA nano- and micro-carriers for pulmonary delivery: challenges and
promises. J Pharm Pharmacol 2012;64:1217e35.
28. Zarena AS, Sankar KU. Design of submicron and nanoparticle delivery
systems using supercritical carbon dioxide-mediated processes: an over-
view. Ther Deliv 2011;2:259e77.
29. Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles in
porous microparticles prepared by supercritical infusion and pressure
quench technology for sustained delivery of bevacizumab. Mol Pharm
2013;10:4676e86.
30. Daull P, Paterson CA, Kuppermann BD, Garrigue JS. A preliminary
evaluation of dexamethasone palmitate emulsion: a novel intravitreal
sustained delivery of corticosteroid for treatment of macular edema. J
Ocul Pharmacol Ther 2013;29:258e69.
31. Haller JA, Bandello F, Belfort Jr R, Blumenkranz MS, Gillies M, Heier J,
et al. Randomized, sham-controlled trial of dexamethasone intravitreal
implant in patients with macular edema due to retinal vein occlusion.
Ophthalmology 2010;117. 1134e46.e3.
32. Haller JA, Bandello F, Belfort Jr R, Blumenkranz MS, Gillies M, Heier J,
et al. Dexamethasone intravitreal implant in patients with macular edema
related to branch or central retinal vein occlusion twelve-month study
results. Ophthalmology 2011;118:2453e60.
33. Calvo P, Ferreras A, Al Adel F, Wang Y, Brent MH. Dexamethasone
intravitreal implant as adjunct therapy for patients with wet age-related
macular degeneration with incomplete response to ranibizumab. Br J
Ophthalmol 2015;99:723e6.
34. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM,
Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a
sustained-release dexamethasone intravitreal implant. Invest Ophthalmol
Vis Sci 2011;52:80e6.
35. Suen WL, Chau Y. Specific uptake of folate-decorated triamcinolone-
encapsulating nanoparticles by retinal pigment epithelium cells enhances
and prolongs antiangiogenic activity. J Control Release 2013;167:21e8.
36. Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R,
Koskimaki JE, et al. Long-term suppression of ocular neovascularization
by intraocular injection of biodegradable polymeric particles containing a
serpin-derived peptide. Biomaterials 2013;34:7544e51.
37. AmriteAC,KompellaUB.Celecoxib inhibits proliferation of retinal pigment
epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-
independent mechanism. J Pharmacol Exp Ther 2008;324:749e58.
38. Palamoor M, Jablonski MM. Synthesis, characterization and in vitro
studies of celecoxib-loaded poly(ortho ester) nanoparticles targeted
for intraocular drug delivery. Colloids Surf B Biointerfaces
2013;112:474e82.
641T.-C. Lin et al. / Journal of the Chinese Medical Association 78 (2015) 635e64139. Boddu SH, Jwala J, Vaishya R, Earla R, Karla PK, Pal D, et al. Novel
nanoparticulate gel formulations of steroids for the treatment of macular
edema. J Ocul Pharmacol Ther 2010;26:37e48.
40. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye
disease. Invest Ophthalmol Vis Sci 2000;41:961e4.
41. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles
and microparticles following subconjunctival administration. J Pharm
Pharmacol 2005;57:1555e63.
42. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al.
Complement factor H variant increases the risk of age-related macular
degeneration. Science 2005;308:419e21.
43. Edwards AO, Ritter 3rd R, Abel KJ, Manning A, Panhuysen C, Farrer LA.
Complement factor H polymorphism and age-related macular degenera-
tion. Science 2005;308:421e4.
44. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al.
Complement factor H polymorphism in age-related macular degeneration.
Science 2005;308:385e9.
45. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ,
Hardisty LI, et al. A common haplotype in the complement regulatory
gene factor H (HF1/CFH) predisposes individuals to age-related macular
degeneration. Proc Natl Acad Sci U S A 2005;102:7227e32.46. Francis PJ, Klein ML. Update on the role of genetics in the onset of age-
related macular degeneration. Clin Ophthalmol 2011;5:1127e33.
47. Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the
complement system in age-related macular degeneration: a review. Clin
Exp Ophthalmol 2012;40:18e26.
48. Wyatt MK, Tsai JY, Mishra S, Campos M, Jaworski C, Fariss RN, et al.
Interaction of complement factor h and fibulin3 in age-related macular
degeneration. PLoS One 2013;8:e68088.
49. Chan CC, Ardeljan D. Molecular pathology of macrophages and
interleukin-17 in age-related macular degeneration. Adv Exp Med Biol
2014;801:193e8.
50. Li Y, Liu X, Zhou T, Kelley MR, Edwards P, Gao H, et al. Inhibition of
APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells
from oxidative stress and reduces choroidal neovascularization. Redox
Biol 2014;2:485e94.
51. Wittchen ES, Nishimura E, McCloskey M, Wang H, Quilliam LA,
Chrzanowska-Wodnicka M, et al. Rap1 GTPase activation and barrier
enhancement in RPE inhibits choroidal neovascularization in vivo. PLoS
One 2013;8:e73070.
